IQVIA Strategy and Business Model

Executive Overview

IQVIA is a global healthcare intelligence and life-sciences services company whose core customers are pharmaceutical, biotechnology, and medical-device manufacturers. The current company was created by the 2016 merger of Quintiles, a contract research organization, and IMS Health, a healthcare data and analytics company, and it rebranded as IQVIA in 2017. Headquartered in Durham, North Carolina, IQVIA operates in more than 100 countries and reported more than $15 billion of revenue in FY2024. Its model combines three businesses that reinforce each other: Technology & Analytics Solutions, which monetizes healthcare data, software, and analytics; Research & Development Solutions, which supports clinical trials and laboratory services; and Contract Sales & Medical Solutions, which provides outsourced field teams, patient support, and related medical services. Strategically, IQVIA sits at an important point in the life-sciences value chain because it can help a client design a study, recruit patients, generate real-world evidence, launch a product, and optimize commercial execution using the same underlying data and technology stack. That mix matters: the clinical business provides scale and client access, while data and technology tend to support more recurring revenue, higher switching costs, and stronger margins.

IQVIA at a Glance

Logo
Common name	IQVIA
Full legal name	IQVIA Holdings Inc.
Headquarters	Durham, North Carolina, United States
Ownership	Public company
Ticker	IQV
Exchange	NYSE - New York Stock Exchange
Market Cap	$28.50B
Revenue (FY2024)	$15.45B
Founding / major historical milestones	Created in 2016 through the merger of Quintiles and IMS Health; roots trace to IMS Health in 1954 and Quintiles in 1982; rebranded as IQVIA in 2017
Industry or industries	Life-sciences services, clinical research outsourcing, healthcare data and analytics, healthcare technology
Key products or services	Clinical research services, healthcare data and information, analytics, real-world evidence, commercial software, outsourced contract sales, medical and patient support services
Geographic footprint	Global; operations and client coverage in more than 100 countries
Business segments as officially reported	Technology & Analytics Solutions; Research & Development Solutions; Contract Sales & Medical Solutions
Company website	https://www.iqvia.com/

1. What Is the Strategy of IQVIA?

Using the Playing to Win framework, IQVIA’s public strategy is to be more than a contract research organization or a healthcare data vendor. Management consistently presents IQVIA as an integrated partner that combines data, technology, analytics, and execution services across the life-sciences value chain.

1. 1a. What is the winning aspiration of IQVIA?

   IQVIA’s winning aspiration is to improve healthcare decision-making and patient outcomes while becoming an indispensable operating partner to life-sciences companies. In practical terms, winning means being the partner clients use from clinical development through launch and commercialization, not just a point solution provider. Public materials emphasize a blend of mission and economics: better evidence generation, more productive trials, better commercial returns for customers, and durable revenue, margin, and cash-flow growth for IQVIA. The company has not centered its public messaging on a single market-share target; instead it frames success around expanding the value of its connected data, technology, and service model.

2. 1b. Where does IQVIA play?

   IQVIA plays primarily in business-to-business healthcare markets. Its core arena is the global life-sciences sector: large pharmaceutical companies, specialty pharma, biotechnology companies, and medical-device manufacturers. It also serves other healthcare stakeholders such as providers, payers, and government or public-health entities where IQVIA’s data and analytics are relevant. Along the value chain, IQVIA participates in market intelligence, commercial analytics, customer engagement software, real-world evidence, clinical trial design and execution, lab services, patient support, and outsourced field commercialization. Geographically, it plays on a global basis, with operations in more than 100 countries.

3. 1c. How does IQVIA plan to win?

   IQVIA plans to win through differentiation, not through being the lowest-cost provider. Its core value proposition is what it calls connected intelligence: combining large-scale healthcare data assets, workflow software, analytics, artificial intelligence, scientific expertise, and global service delivery. Few competitors span as much of the molecule-to-market workflow. That matters because a pharmaceutical customer often prefers fewer vendors, cleaner data handoffs, and better visibility across development and commercialization. IQVIA also benefits from scale, regulatory know-how, and long client relationships. In more price-competitive areas such as clinical outsourcing, IQVIA’s argument is that it can reduce execution risk, improve speed, and produce better decisions, which supports pricing more effectively than a pure labor-arbitrage model.

4. 1d. What capabilities must IQVIA have in place?

   IQVIA needs several hard-to-build capabilities. The first is access to broad, privacy-compliant healthcare data and the ability to normalize, link, and govern that data. The second is software and analytics capability, including artificial intelligence, statistical modeling, workflow design, and secure enterprise delivery. The third is operational execution in regulated settings: clinical trial management, site and patient recruitment, laboratory operations, medical affairs support, and outsourced field execution. A fourth capability is industry trust. Because customers use IQVIA in high-stakes regulated processes, quality systems, security, privacy, and scientific credibility are essential. Finally, IQVIA needs strong enterprise account management so it can cross-sell across segments rather than operating as disconnected businesses.

5. 1e. What management systems does IQVIA require?

   IQVIA requires management systems that balance long-cycle services execution with software and data economics. Public disclosures indicate the importance of segment-level reporting across Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. In Research & Development Solutions, bookings, backlog, conversion of backlog to revenue, utilization, and trial quality are critical. In Technology & Analytics Solutions, recurring revenue, renewal rates, product adoption, and cross-sell matter more. Across the company, management systems must also track compliance, data privacy, information security, talent retention, and cash generation. Capital allocation is another system-level priority: funding product development and selective acquisitions while managing leverage and returning capital through repurchases where management sees fit.

2. What Are the Current Strategic Initiatives of IQVIA?

In FY2024 disclosures and investor communications, IQVIA’s strategic initiatives were less about a dramatic portfolio rewrite and more about deepening the integration of data, software, and services. Several themes stand out.

Expanding AI-enabled and analytics-rich offerings

IQVIA has been pushing more artificial intelligence, advanced analytics, and workflow automation into both clinical and commercial products. This includes embedding AI into search, analysis, forecasting, targeting, and workflow tools rather than treating AI as a standalone add-on. The strategic objective is twofold: improve customer outcomes and raise the value of IQVIA’s software and data layers.

Making clinical development more technology-enabled and site-centered

IQVIA continues to invest in digital and tech-enabled trial execution, including tools that help sponsors and research sites manage workflows, reduce friction, and improve enrollment and study execution. Public materials have emphasized patient engagement, site enablement, hybrid and decentralized elements of trial operations, and tighter integration between technology and service delivery. This is a direct response to industry-wide pressure to shorten development timelines and improve site productivity.

Growing higher-value data, real-world evidence, and commercial intelligence

IQVIA’s data assets remain a core strategic lever. Management has continued to emphasize information offerings, real-world evidence, and analytics that help customers with market understanding, launch planning, health economics, outcomes research, and post-market decision-making. These offerings matter strategically because they tend to be sticky, analytically differentiated, and supportive of recurring or repeat business.

Deepening relationships with biotech and emerging biopharma

IQVIA has publicly highlighted the importance of serving not only large pharmaceutical clients but also smaller and mid-sized biotechnology companies. These customers can be attractive because they often need broader outsourced support across development, regulatory, and commercialization activities. The opportunity is meaningful, although it is also more exposed to biotech funding cycles than large pharma demand.

Driving cross-segment selling

A recurring strategic theme is getting more value from IQVIA’s breadth. Management regularly positions the company as one platform serving multiple needs, from trial design to launch execution. That implies an initiative around account management, packaging, and internal coordination: the company benefits when a client using clinical services also buys commercial analytics, or when a data customer expands into software and patient support services.

Protecting margins through productivity and delivery discipline

IQVIA has also focused on operational efficiency. For a company with large expert labor pools, margins depend heavily on utilization, execution quality, automation, and disciplined delivery. Public commentary has pointed to productivity programs, technology enablement, and global delivery leverage as important contributors to profitability alongside topline growth.

3. What Is the Business Model of IQVIA?

What customers actually buy

Customers buy a mix of data, software, analytics, and outsourced execution. A pharmaceutical company might buy prescription and claims data, launch analytics, customer-engagement software, and real-world evidence studies from Technology & Analytics Solutions. The same company might also outsource clinical trial execution, site monitoring, patient recruitment, and lab work to Research & Development Solutions. Later, it might use Contract Sales & Medical Solutions for outsourced field teams, nurse educators, patient support, or reimbursement services.

Recurring versus one-time revenue

IQVIA’s revenue is a blend. Technology & Analytics Solutions appears to have the highest recurring or renewal-driven component because data subscriptions, software licenses, and ongoing analytics relationships can be renewed and expanded over time. Research & Development Solutions is not a subscription model, but it is highly repeat-driven: drug pipelines create multiyear demand, and customers often run multiple studies across years. Contract Sales & Medical Solutions is contract-based and can be episodic, but it also benefits from repeat programs tied to launches, patient support, and field deployment.

How pricing power works

IQVIA’s pricing power is strongest where it combines proprietary or hard-to-replicate data with workflow software and domain expertise. In those areas, switching costs can be meaningful and the cost of a bad decision for the customer is high. Pricing is weaker in more labor-intensive, procurement-driven services where sponsors can compare bids across CROs or outsourced field providers. Even there, IQVIA can defend price when it can show lower operational risk, better compliance, or faster execution.

Why the business mix matters

The mix matters because the three segments have different economics. Research & Development Solutions is the largest revenue engine and provides scale, backlog visibility, and strategic access to clients. Technology & Analytics Solutions likely contributes disproportionately to differentiation and margin because data and software are more scalable than labor-based services. Contract Sales & Medical Solutions expands IQVIA’s role in commercialization and helps the company participate later in the product lifecycle.

What drives margins and cash generation

Margins are driven by several factors: the share of revenue coming from software and data versus labor-heavy services; utilization of clinical and analytics staff; trial execution quality; site startup and patient enrollment efficiency; the cost of acquiring and maintaining data rights; and global delivery leverage. Cash generation benefits from relatively modest physical capital needs compared with manufacturing businesses, but working capital still matters because receivables, milestone payments, and project timing can move cash conversion materially. The overall revenue model is best described as a mix of subscription, license, fixed-fee project work, time-and-materials services, and multi-year outsourcing contracts.

4. What Products and Services Does IQVIA Sell?

Technology & Analytics Solutions

• Healthcare information and market measurement data
• Real-world data and real-world evidence services
• Commercial analytics, launch analytics, and consulting-style decision support
• Life-sciences workflow and customer-engagement software, including commercial and medical-facing applications
• Compliance, targeting, segmentation, and omnichannel engagement tools

This segment is strategically important because it contains much of IQVIA’s proprietary data, analytics, and software layer. It is central to the company’s “connected intelligence” positioning and appears to be one of the main sources of recurring revenue and switching costs.

Research & Development Solutions

• Full-service clinical trial outsourcing from study design through execution
• Functional service provision, including monitoring and trial operations support
• Patient recruitment and engagement services
• Site management and technology-enabled trial workflows
• Laboratory and related clinical testing services

This is IQVIA’s largest revenue engine and the business that puts the company directly into the flow of global drug development. It tends to be more labor- and execution-intensive than Technology & Analytics Solutions, but it creates deep client relationships and cross-sell opportunities.

Contract Sales & Medical Solutions

• Outsourced field sales teams
• Medical and clinical educator programs
• Nurse educator and patient support services
• Reimbursement, access, and adherence support
• Other outsourced commercialization and medical solutions

This segment is smaller than the other two, but it extends IQVIA into launch and commercialization execution. It matters especially for clients that want a single partner from development through commercial scale-up.

Legacy versus newer growth offerings

IQVIA’s legacy heritage includes healthcare information services from IMS Health and contract research from Quintiles. Newer growth emphasis appears to be in real-world evidence, cloud and workflow software, AI-enabled analytics, digital and omnichannel commercial solutions, and more technology-enabled clinical development tools.

5. What Are the Key Competitors or Peers of IQVIA?

IQVIA competes in several adjacent markets, so the peer set varies by segment. The most relevant competitors include the following.

No single competitor matches IQVIA perfectly across all three reporting segments. That is part of IQVIA’s strategic position: some rivals are strong in clinical services, some in software, and some in commercialization, but fewer combine all three with comparable data assets.

6. What Is the Marketing Strategy of IQVIA?

IQVIA’s marketing strategy is primarily enterprise-focused, credibility-led, and closely tied to sales. This is not a mass-market brand-advertising business. Its buyers are pharmaceutical executives, clinical operations leaders, medical affairs teams, commercial leaders, procurement groups, and health-economics decision makers. That means scientific credibility, case evidence, client references, and thought leadership matter more than consumer-style promotion.

• Account-based marketing: Marketing appears tightly aligned with strategic-account selling, especially for large pharma and multinational clients.
• Thought leadership: IQVIA publishes market outlooks, research, industry commentary, and solution content to demonstrate expertise and stay close to senior decision makers.
• Brand architecture: The corporate brand does meaningful work. IQVIA markets the idea of an integrated platform under themes such as connected intelligence, rather than leading with dozens of unrelated sub-brands.
• Event and field marketing: Industry conferences, therapeutic-area events, and client forums are likely important because life-sciences buying cycles are relationship- and expertise-driven.
• Supporting, not standalone, capability: Public disclosures suggest marketing is an important enabler of enterprise selling, but not the company’s primary competitive moat. The real differentiation sits in data, technology, domain expertise, and delivery execution.

Because IQVIA sells complex solutions, marketing and product packaging are closely linked. The company’s ability to explain integrated value across segments is strategically important, especially when competing against point-solution vendors.

7. What Are the Key Customer Segments of IQVIA?

IQVIA’s customer base is broad within healthcare, but the economic center of gravity is clearly life sciences.

• Large global pharmaceutical companies: These are among IQVIA’s most important customers because they buy across multiple categories, including data, analytics, software, clinical services, and commercialization support.
• Biotechnology and emerging biopharma companies: These customers often outsource more aggressively because they have smaller internal infrastructures. They are strategically attractive, although demand can be more sensitive to capital-market conditions.
• Medical-device and diagnostics companies: These customers use commercial analytics, evidence-generation services, and selected commercialization support.
• Providers, payers, and government or public-health entities: These are relevant customers mainly for data, analytics, and technology offerings rather than the full development-services stack.
• Medical, commercial, and market-access functions within clients: Inside a customer account, IQVIA often sells to different buying centers, which increases cross-sell potential but also makes enterprise coordination important.

IQVIA appears diversified across many clients and sub-markets rather than dependent on one narrow end market. Even so, the company is closely tied to the health of biopharma research, launch activity, and commercial spending.

8. What Is the Sales Model of IQVIA?

IQVIA mainly sells through a direct enterprise sales model. Its offerings are too complex and regulated to rely primarily on broad reseller channels.

Direct strategic-account selling

Large pharmaceutical and multinational clients are typically covered through strategic or global account teams. This matters because one customer may buy clinical development services, commercial software, data, and patient-support programs from different parts of IQVIA. A coordinated account structure supports cross-sell and larger wallet share.

RFP-driven selling in clinical services

In Research & Development Solutions, a significant share of sales is tied to requests for proposal, therapeutic expertise, bid defense, and operational track record. This is a long-cycle sales process where backlog matters as much as near-term bookings.

Renewal and expansion in data and software

In Technology & Analytics Solutions, the sales motion includes renewal, upsell, and expansion of subscriptions or software deployments. Once IQVIA’s data and workflow tools are embedded in decision processes, account expansion can be as important as winning entirely new logos.

Service deployment as part of the sale

For Contract Sales & Medical Solutions, the sale is often inseparable from staffing, training, and service operations. Winning the contract is only the beginning; delivery quality determines renewal potential.

How channel structure affects growth and pricing

The direct model gives IQVIA better control over complex solution design, customer intimacy, and pricing discussions. It also creates execution demands: the company needs strong account management, better packaging across segments, and disciplined handoffs between sales and delivery. Those areas are often fertile ground for independent consultants because even strong businesses can struggle to coordinate pricing, proposals, and cross-segment selling at scale.

9. In What Geographies Does IQVIA Operate?

IQVIA has a genuinely global footprint. Company materials describe operations and customer coverage in more than 100 countries. Unlike a manufacturer, IQVIA’s footprint is defined less by factories and more by offices, delivery centers, laboratories, clinical-research infrastructure, and field teams.

• North America: The United States is likely the single most important market because of the scale of the pharmaceutical industry, healthcare data availability, and commercial demand.
• Europe: Europe is important for both customers and clinical trial execution, with established pharmaceutical markets and broad site networks.
• Asia-Pacific: This region matters both for multinational trial execution and for delivery talent, especially in analytics, technology, and operations support.
• Latin America, Middle East, and Africa: These regions expand trial reach, data coverage, and commercialization support in selected markets.

IQVIA appears geographically diversified rather than concentrated in a handful of countries. That diversification is strategically useful because drug development and commercialization are global, but it also raises execution complexity around privacy, regulation, data localization, and talent management.

10. Who Are the Owners of IQVIA?

IQVIA is a publicly traded company listed under the ticker IQV. As of public filings in early 2025, it appeared to be widely held, with no controlling shareholder. Large holders reported in institutional filings around that period included major asset managers such as The Vanguard Group and BlackRock. Like many large U.S. public companies, ownership is primarily institutional rather than founder-controlled or family-controlled.

11. How Is IQVIA Organized?

Legally, IQVIA is a public holding company. Operationally and for external reporting, it is organized into three reportable segments:

• Technology & Analytics Solutions: data, analytics, software, and technology-enabled information offerings
• Research & Development Solutions: clinical research services and related laboratory and development support
• Contract Sales & Medical Solutions: outsourced commercialization, patient support, and medical solutions

Practically, IQVIA appears to run a matrix that combines these segment businesses with geographic delivery and shared corporate functions such as finance, technology, compliance, and human resources. The company’s strategic challenge is to preserve segment focus while still acting like one firm for large clients. That is a classic coordination problem in diversified professional and technology services businesses.

12. How Does IQVIA Operate?

IQVIA operates through three linked engines: a data-and-software engine, a clinical-delivery engine, and a commercialization-services engine.

Data and software operations

IQVIA acquires, curates, normalizes, and analyzes healthcare datasets, then turns those data into information products, analytics, and workflow software. Day-to-day operations include data ingestion, privacy and compliance controls, product management, software development, implementation, and client support. Reliability, security, and the ability to link disparate healthcare data safely are essential operating requirements.

Clinical-delivery operations

In Research & Development Solutions, IQVIA runs global study operations: protocol planning support, site identification, patient recruitment, clinical monitoring, project management, data handling, and related lab activities. This is execution-heavy work. Performance depends on staffing quality, therapeutic expertise, patient enrollment speed, site productivity, and regulatory compliance.

Commercial and medical service operations

In Contract Sales & Medical Solutions, IQVIA recruits, trains, deploys, and manages field and patient-support personnel on behalf of clients. Day-to-day operations include workforce scheduling, quality control, compliance training, program management, and performance measurement against customer goals.

Key operational complexities

Several bottlenecks matter. In clinical services, site activation and patient recruitment can slow revenue conversion and hurt margins. In data and software, data rights, integration quality, and privacy controls are mission critical. Across the whole company, utilization of skilled labor is a major driver of profitability. IQVIA’s operating model is therefore part technology platform, part regulated services network, and part expert labor business.

13. What Are the Growth Opportunities for IQVIA?

Based on public strategy statements and industry structure, the most plausible growth opportunities for IQVIA include the following.

• More outsourced drug-development spend: Biopharma companies continue to rely on external partners for clinical execution, especially as trials become more complex and global.
• Higher penetration of real-world evidence and analytics: Payers, regulators, and drug makers increasingly want real-world data and evidence to support development, access, and commercialization decisions.
• AI-enabled product expansion: Embedding AI into trial design, site selection, targeting, content, forecasting, and workflow software can raise product value and improve internal productivity.
• Cross-selling across the platform: A clinical-services client can become a data client; a data client can become a software client; a launch client can add field solutions. This is one of IQVIA’s clearest internal growth levers.
• Biotech and emerging-biopharma penetration: Smaller innovators often need a broader outsourced stack, which fits IQVIA’s integrated model if the company packages it well.
• Commercial execution and omnichannel demand: Life-sciences customers continue to seek better physician engagement, launch effectiveness, and patient-support models, especially as commercialization becomes more digital and data-driven.
• International growth: Broader geographic coverage in data, trials, and commercialization can support global programs and selected emerging-market opportunities.

The main constraints are also clear: biotech funding volatility, sponsor procurement pressure, competition in CRO markets, privacy and data-governance requirements, and the operational challenge of coordinating a large multi-segment organization.

14. What Is the History of IQVIA?

• 1954: IMS Health’s origins began in healthcare information and market measurement.
• 1982: Quintiles was founded by Dennis Gillings and built into a major contract research organization.
• 2010s: Both predecessor businesses went through public-private-public transitions that reflected private-equity interest in healthcare data and outsourced drug-development services.
• 2013: Quintiles returned to the public markets through an initial public offering.
• 2014: IMS Health also returned to the public markets after a prior period of private ownership.
• 2016: Quintiles and IMS Health merged, creating QuintilesIMS and establishing the foundation for today’s combined data-plus-services model.
• 2017: The company adopted the IQVIA name and brand.
• 2021: IQVIA acquired Quest Diagnostics’ remaining stake in Q2 Solutions, bringing that laboratory business fully under IQVIA ownership.

The defining historical event was the 2016 merger. It changed the company from a strong but narrower CRO into a broader healthcare intelligence platform with a more differentiated position than either predecessor had on its own.

15. How Is IQVIA Using AI?

IQVIA has used advanced analytics and machine learning for years in areas such as forecasting, targeting, patient identification, site selection, and pattern detection in healthcare data. The more recent strategic shift has been toward broader artificial intelligence and generative-AI deployment across products and workflows.

As of 2024, IQVIA was publicly positioning healthcare-grade AI as part of its product strategy. Live use cases appear to include AI-supported analytics, workflow assistance, search and summarization, and decision support embedded in clinical and commercial applications. Management has also discussed broader generative-AI opportunities in knowledge work, content creation, protocol support, and productivity workflows, though those should be understood as a mix of already deployed tools and still-scaling initiatives rather than one completed enterprise rollout. IQVIA’s edge is not generic AI alone; it is AI applied to regulated healthcare workflows, domain-specific data, privacy controls, and customer decision processes.

16. What Is the Technology Strategy of IQVIA?

Technology is central to IQVIA’s competitiveness both as an internal enabler and as part of the customer offering. The company’s strategy is to connect data, analytics, and workflow tools so that clients can move from insight to execution inside the same ecosystem. That is very different from using software only to support a labor-based services model.

Externally, IQVIA sells technology in areas such as commercial engagement, analytics, data access, and clinical workflow support. Internally, it uses technology to automate delivery, improve productivity, standardize quality, and support global collaboration across studies and customer accounts. The most important underlying capabilities appear to be data architecture, privacy-safe data linkage, analytics engines, cloud-delivered workflow tools, and interoperability across clinical and commercial use cases.

Technology also matters strategically because it changes IQVIA’s mix. The more the company can deliver value through reusable software and data platforms, the less dependent it is on pure headcount growth. That does not replace services, but it can improve margins, deepen customer lock-in, and make the company harder to replicate.

17. What Is the Finance Strategy of IQVIA?

IQVIA’s finance strategy appears built around three priorities: investing in product and capability development, maintaining disciplined leverage and liquidity, and returning excess capital primarily through share repurchases rather than a regular dividend. As of FY2024, IQVIA did not have a regular dividend, which is consistent with a company that still prioritizes reinvestment, deal flexibility, and balance-sheet management.

The business has attractive cash-generation characteristics relative to many service businesses because it benefits from recurring data and technology revenue, scale in outsourced services, and modest physical capital intensity. Even so, working capital and collections matter because project timing, milestone billing, and receivables can affect cash conversion. Management attention to adjusted earnings, margin expansion, and free cash flow is therefore strategically sensible.

Finance also supports strategy through mix management. A richer contribution from software, analytics, and data can support stronger margins, while disciplined project execution protects profitability in the services businesses. The company’s balance sheet still reflects the legacy of private-equity ownership and large corporate transactions, so capital allocation discipline remains important.

18. What Major Acquisitions Has IQVIA Made?

Acquisitions have played an important role in IQVIA’s formation and capability building, but the company is not best understood as a serial roll-up. The major strategic transaction was the 2016 combination of Quintiles and IMS Health, which created the current model by bringing clinical research services together with healthcare data, analytics, and technology.

• 2016: Quintiles + IMS Health — the transformational merger that created the foundation for today’s IQVIA.
• 2021: Quest Diagnostics’ remaining stake in Q2 Solutions — brought the laboratory joint venture fully in-house and strengthened IQVIA’s development-services offering.

Since then, public strategy has suggested a preference for selective, capability-led acquisitions rather than recurring megadeals. In other words, M&A appears to be a tool for adding data, technology, or service capabilities, not the sole engine of growth.

19. How Companies Like IQVIA Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like IQVIA use Umbrex when they need high-caliber problem solving and execution support, but do not need a full consulting team with large-firm overhead. Because IQVIA operates at the intersection of strategy, operations, technology, data, commercialization, and clinical services, the range of useful independent-consulting projects is broad.

• Develop a growth strategy for AI-enabled offerings across clinical, commercial, and analytics workflows.
• Redesign pricing and packaging for data, analytics, and software products to improve renewal rates and expansion revenue.
• Create a segment-specific go-to-market plan for emerging biotech customers, including service bundles and account coverage.
• Map cross-sell opportunities across Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
• Improve clinical-operations productivity through study-startup redesign, site-network prioritization, and enrollment process optimization.
• Assess commercial effectiveness for outsourced field teams, patient support, and omnichannel engagement programs.
• Design an AI governance and operating model that balances innovation with healthcare privacy, compliance, and quality requirements.
• Evaluate tuck-in acquisition targets in healthcare data, workflow software, or commercialization services and support post-merger integration.
• Optimize global delivery footprint, role design, and spans-and-layers across analytics, technology, and service operations.
• Run working-capital and cash-conversion improvement programs focused on billing discipline, receivables, and project economics.